Affinity Asset Advisors, LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Affinity Asset Advisors, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $1.47 Million - $1.98 Million	10,000 Added 33.33%	40,000 $5.98 Million
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $4.54 Million - $5.9 Million	30,000 New	30,000 $5.74 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $4.24 Million - $5.19 Million	-25,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $3.22 Million - $4.42 Million	25,000 New	25,000 $4.24 Million

650

109M

1.28M

1.23M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.